Hymovis One | Fidia Jointcare USA

Unique formulation

The ONLY non-crosslinked, non-avian (bacterially fermented) Single-Injection Hyaluronan (HA) Viscoelastic Hydrogel trusted for osteoarthritis (OA) knee pain relief

HYMOVIS^® ONE is the ONLY non-crosslinked, single-injection, HA hydrogel viscosupplement available on the market in the US

HYMOVIS^® ONE is a product developed by Fidia, a company leading the way for over 60 years, in research and development of patented hyaluronic acid technologies. HYMOVIS^® ONE, whose patented hyaluronic acid (HA), HYADD^®4, a hexadecylamide derivative of HA, is a true hydrogel that exhibits highly viscoelastic effects with a complete structural recovery of its molecular structure, even after repeated mechanical stress ⁴, thanks to the patented MO.RE. technology*

*Preclinical test data may not be indicative of human clinical outcomes.

WHAT IS HYMOVIS^® ONE?

Viscoelastic hydrogel

Viscous (thick) gel-like sterile solution made from highly purified chemically modified hyaluronan²

HYADD^®4

Minimally modified molecule with alkyl side chains, without any chemical cross-linking^1,7

MO.RE. (MObile REticulum) TECHNOLOGY

A network stabilized by reversible hydrophobic interactions, conferring high viscoelasticity and stability, resulting in an HA similar to the HA

found in the synovial fluid present in the human joint^1,2,7

Indication

HYMOVIS^® ONE is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics (e.g., acetaminophen).

Important Safety Information

HYMOVIS^® ONE is contraindicated in patients with known hypersensitivity (allergy) to hyaluronate preparations or gram-positive bacterial proteins. Do not administer HYMOVIS^® ONE to patients with infections or skin diseases in the area of the injection site or joint. The safety and effectiveness of HYMOVIS^® ONE has not been established in pregnant women, nursing mothers, or children or for use in joints other than the knee, or concomitant use with other intra-articular (IA) injections. The effectiveness of repeat treatment cycles of HYMOVIS^® ONE has not been established. No serious adverse events or pseudoseptic reactions were reported in the HYMOVIS^® ONE clinical study. The adverse events experienced and reported in the HYMOVIS^® ONE clinical study were joint swelling, metatarsalgia, neck pain and headache.

Rx Only. See package insert for full prescribing information including indications, contraindications, adverse events, warnings, precautions, and side effects.

Scientific Evidence

CLINICAL SAFETY AND EFFICACY

PROVIDER REIMBURSEMENT AND SUPPORT

Patients Resources

HOW TO Order

References:
1. HYMOVIS^® ONE Summary of Safety and Effectiveness Data (SSED) P150010/S005

2. HYMOVIS^® ONE Package Insert. Fidia Farmaceutici S.p.A., Abano Terme, Italy; 2025.

4. Finelli I, Chiessi E, Galesso D, Renier D, Paradossi G. A new viscosupplement based on
partially hydrophobic hyaluronic acid: a comparative study. Biorheology. 2011;48(5):263-275

7. HYMOVIS^® ONE data on file, FIDIA FARMACEUTICI S.p.A., ITALY.

Unique formulation